ALX Oncology Holdings (ALXO)
(Delayed Data from NSDQ)
$0.52 USD
-0.05 (-8.70%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $0.52 0.00 (0.37%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ALXO 0.52 -0.05(-8.70%)
Will ALXO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALXO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALXO
ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
ALXO: What are Zacks experts saying now?
Zacks Private Portfolio Services
ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for ALXO
Jazz Pharmaceuticals: I See Big Potential In This Stock As An Investor
ALX Oncology Confirms Directors at Annual Meeting
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference | ALXO Stock News
Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and ALX Oncology Holdings (ALXO)
ALX Oncology Holdings (ALXO) Gets a Buy from Piper Sandler